公开(公告)号：US20180071366A1

公开(公告)日：2018-03-15

申请号：US15698743

申请日：2017-09-08

申请人： Zealand Pharma A/S ,  Boehringer Ingelheim International GmbH

发明人： Jesper Mosolff MATHIESEN ,  Jesper Skodborg VILLADSEN ,  Lise GIEHM ,  Henrik Kofoed MUNCH ,  Dieter Wolfgang HAMPRECHT ,  Alexander HEIM-RIETHER ,  Giacomo FOSSATI

IPC分类号： A61K38/22 ,  C07K14/575

CPC分类号： A61K38/22 ,  C07K14/575

摘要： The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.

公开(公告)号：US20210346468A1

公开(公告)日：2021-11-11

申请号：US17381373

申请日：2021-07-21

申请人： Zealand Pharma A/S

发明人： Jesper Mosolff MATHIESEN ,  Jesper Skodborg VILLADSEN ,  Lise GIEHM ,  Henrik Kofoed MUNCH ,  Dieter Wolfgang HAMPRECHT ,  Alexander HEIM-RIETHER ,  Giacomo FOSSATI

IPC分类号： A61K38/22 ,  C07K14/575

摘要： The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.

公开(公告)号：US20190134159A1

公开(公告)日：2019-05-09

申请号：US16050102

申请日：2018-07-31

申请人： Zealand Pharma A/S

发明人： Jesper Mosolff MATHIESEN ,  Jesper Skodborg VILLADSEN ,  Lise GIEHM ,  Henrik Kofoed MUNCH ,  Dieter Wolfgang HAMPRECHT ,  Alexander HEIM-RIETHER ,  Giacomo FOSSATI

IPC分类号： A61K38/22 ,  C07K14/575

摘要： The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.